Hemodialysis patients make long-lived antibodies against SARS-CoV-2 that may be associated with reduced reinfection.
Banham, Gemma D Godlee, Alexandra Faustini, Sian E Cunningham, Adam F Richter, Alex Harper, Lorraine
Banham, Gemma D
Godlee, Alexandra
Faustini, Sian E
Cunningham, Adam F
Richter, Alex
Harper, Lorraine
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-08-02
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.
Citation
Banham GD, Godlee A, Faustini SE, Cunningham AF, Richter A, Harper L; COVID-HD Birmingham Study Group. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. J Am Soc Nephrol. 2021 Sep;32(9):2140-2142. doi: 10.1681/ASN.2021020188. Epub 2021 Aug 2
Type
Article